Hemoglobinopathies Market Research Report - Forecast till 2030

Hemoglobinopathies Market Research Report: Information by Type (Thalassemia (Alpha Thalassemia, Beta Thalassemia), Sickle Cell Disease and other Hb Variant Diseases), Treatment (Stem-cell Transplantation, Blood Transfusions, Analgesics, Antibiotics, ACE inhibitors, Hydroxyurea), End User (Hospitals & Clinics, Diagnostics Laboratories and others) - Forecast till 2030

ID: MRFR/HC/6626-HCR | 90 Pages | Published By Kinjoll Dey on March 2023         

Hemoglobinopathies Market Speak to Analyst Request a Free Sample

Hemoglobinopathies Market

The Hemoglobinopathies Market is projected to register a CAGR of around 9.80% over the forecast period.

Segmentation
By Type Thalassemia (Alpha Thalassemia Beta Thalassemia) Sickle Cell Disease other Hb Variant Diseases
By Treatment Stem-cell Transplantation Blood Transfusions Analgesics Antibiotics ACE inhibitors Hydroxyurea
By End User Hospitals & Clinics Diagnostics Laboratories
Key Players
Companies Profiled   Sanofi    Sangamo Therapeutics Inc.    Global Blood Therapeutics    Bluebird Bio Inc.    Emmaus Life Sciences Inc.    Prolong Pharmaceuticals    Celgene Corporation    Alnylam Pharmaceuticals    Gamida Cell    Acceleron Pharma    Mast Therapeutic
Drivers
Market Driving Forces   The rising prevalence of hemoglobin disorders such as sickle cell anemia    thalassemia Hb C    Hb E is estimated to be the high impact rendering driver of the market.
Request a Free Sample

Hemoglobinopathies Market Scenario


The hemoglobinopathies market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 5,800 million in 2018 and is projected to register a CAGR of around 9.80% over the forecast period.

Hemoglobinopathies is a group of blood disorders such as sickle cell disease, thalassemia, and many others. It is considered the most common inherited disease across the globe. Also, nowadays, hemoglobinopathies have become much more common in central and northern Europe, including Germany, due to immigration.

The rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering driver of the market. According to the WHO, hemoglobin disorders are endemic in over 60% of the 229 countries affecting over 70% of births. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2015, the initial screening of newborns to identify sickle cell disease (SCD) along with other hemoglobin disorders such as, alpha (╬▒) and beta (╬▓) thalassemia have also gained significant attention in recent years due to the change in the US demographics.

Unhygienic and poor healthcare infrastructure are some of the factors attributing to increase in the base of the target population in low-income regions such as South-East Asia, Mediterranean basin, and African region which will drive the market growth over the forecast period. However, the lack of treatment and diagnosis awareness may hamper the growth of the hemoglobinopathies market during the forecast period.

Hemoglobinopathies Market Segmentation

The global hemoglobinopathies market is segmented based on type, treatment, end users, and region.

The global market for hemoglobinopathies, by type, is segmented into thalassemia, sickle cell disease, and other Hb variants diseases. Thalassemia is further classified as alpha thalassemia and beta thalassemia. Based on treatment, the market is classified into stem-cell transplantation, blood transfusions, analgesics, antibiotics, ACE inhibitors, and hydroxyurea. The market by end user has been classified into hospitals and clinics, diagnostics laboratories, and others. The sickle cell disease segment is expected to hold the largest market share of the hemoglobinopathies market owing to the presence of strong product pipelines such as Lent Globin and rising prevalence of sickle cell disease. Also, based on treatment, the blood transfusion segment holds the largest market share owing to significant success rate and increasing adoption of this treatment option.

In the current scope of the study, the segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The hemoglobinopathies market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European hemoglobinopathies market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The hemoglobinopathies market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hemoglobinopathies market in the Middle East and Africa has been segmented into the Middle East and Africa.

Hemoglobinopathies Market Key Players



  • Sanofi

  • Sangamo Therapeutics, Inc.

  • Global Blood Therapeutics

  • Neusoft Medical Systems Co., Ltd

  • Bluebird Bio, Inc.

  • Emmaus Life Sciences Inc.

  • Prolong Pharmaceuticals

  • Celgene Corporation

  • Alnylam Pharmaceuticals

  • Gamida Cell

  • Acceleron Pharma

  • Mast Therapeutic

  • HemaQuest Pharmaceuticals

  • Invenux



Regional Market Summary

Global Hemoglobinopathies Market Share (%), by Region, 2017  Hemoglobinopathies Market_Image

Sources: MRFR Analysis

The Americas dominated the global market for hemoglobinopathies owing to the rising geriatric population within the region. As per the data suggested by the American Society of Hematology approximately 70,000 to 100,000 Americans have sickle cell disease, the most common form of an inherited blood disorder.

As per the Centers for Disease Control and Prevention (CDC) in 2010, the US incidence estimate for sickle cell trait (based on information provided by 13 states) was 73.1 cases per 1,000 black newborns, 3.0 cases per 1,000 white newborns, and 2.2 cases per 1,000 Asian or Pacific Islander newborns. The incidence estimates for Hispanic ethnicity (within 13 states) was 6.9 cases per 1,000 Hispanic newborns.

The rising participation of market players is also strongly impacting the growth of the Americas hemoglobinopathies market. For instance, in 2018, in Europe, Sanofi launched the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP), bringing a new treatment option to patients who previously had none. In the US, this treatment was approved by the FDA in February 2019.

According to the Centers for Disease Control and Prevention (CDC), SCD affects approximately 100,000 Americans, which occurs among about one out of every 365 black or African American births.

Asia-Pacific (APAC) is expected to represent a phenomenal market growth throughout the forecast period due to the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E.

On the other hand, the Middle East and Africa held the least share in the global hemoglobinopathies market due to the low economic development, especially within the African region.

Hemoglobinopathies Market Segmentation

Global Hemoglobinopathies Market, by Type




  • Thalassemia

    • Alpha Thalassemia

    • Beta Thalassemia



  • Sickle Cell Disease

  • Other Hb Variants Diseases



Global Hemoglobinopathies Market, by Treatment



  • Stem-Cell Transplantation

  • Blood Transfusions

  • Analgesics

  • Antibiotics

  • Ace Inhibitors

  • Hydroxyurea



Global Hemoglobinopathies Market, by End User    



  • Hospitals & Clinics

  • Diagnostics Laboratories

  • Others



Global Hemoglobinopathies Market, by Region




  • Americas


    • North America

      • US

      • Canada



    • Latin America






  • Europe


    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe






  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific






  • Middle East & Africa

    • Middle East

    • Africa






Intended Audience 



  • Pharmaceutical companies

  • Government and private laboratories

  • Research and development (R&D) companies

  • Research laboratories

  • Market research and consulting service providers




Report Scope:

Report Attribute/Metric Details
  Market Size   USD 5,800 Million (2030)
  CAGR   9.80% (2020-2030)
  Base Year   2019
  Forecast Period   2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Sanofi, Sangamo Therapeutics Inc., Global Blood Therapeutics, Bluebird Bio Inc., Emmaus Life Sciences Inc., Prolong Pharmaceuticals, Celgene Corporation, Alnylam Pharmaceuticals, Gamida Cell, Acceleron Pharma, Mast Therapeutic, HemaQuest Pharmaceuticals, and Invenux.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   The increasing prevalence of hemoglobin-related disorders


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

global market was valued at USD 5.8 billion in 2020.

Hemoglobinopathies Market is expected to exhibit a strong 9.80% CAGR over the forecast period from 2020 to 2030.

The increasing prevalence of hemoglobin-related disorders is the major driver for the market.

Lack of awareness among consumers and the presence of poor healthcare infrastructure in developing parts of the world are the key restraints on the market.

Leading players in the global hemoglobinopathies market include Sanofi, Emmaus Life Sciences, Gamida Cell, Invenux, Global Blood Therapeutics, Sangamo Therapeutics, Acceleron Pharma, Prolong Pharmaceuticals, and Bluebird Bio Inc., among others.